SCM
CRNX

Suvretta Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Suvretta Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.4M Buy
1,186,279
+142,400
+14% +$5.29M 0.81% 41
2026
Q1 		$37.9M Buy
+1,043,879
New +$46.6M 0.97% 36
2022
Q3 		– Sell
-1,125,112
Closed -$21M – 76
2022
Q2 		$21M Buy
+1,125,112
New +$22.5M 0.8% 42

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Suvretta Capital Management's CRNX Position: Q2 2026 in Review

Suvretta Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 14% in Q2 2026, buying an estimated $5.29M and bringing the position to 1,186,279 shares worth $44.4M. The position accounts for 0.81% of the portfolio, ranked #41.

Suvretta Capital Management first reported a position in CRNX in Q2 2022 and has held it in 3 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Suvretta Capital Management held 1,186,279 shares of Crinetics Pharmaceuticals worth $44.4M as of Q2 2026.
  • Suvretta Capital Management bought 142,400 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $5.29M.
  • Crinetics Pharmaceuticals made up 0.81% of Suvretta Capital Management's portfolio in Q2 2026, its #41 holding.
  • Suvretta Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2022 and has held it in 3 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.